Privo Technologies Completes Phase 2 Run-In for PRV111 Oral Cancer Patch, Shows Promise for Surgery-Sparing Treatment
核心洞察
Privo Technologies (搜索) completed enrollment in the Phase 2 run-in portion of its CLN-004 trial evaluating PRV111, a nano-engineered chemotherapy patch for oral cavity cancers.
Initial observations showed encouraging safety and local tumor response with no systemic toxicity, with some patients avoiding planned surgeries due to absence of visible disease.
PRV111 is a topical patch delivering cisplatin nanoparticles directly to oral lesions, designed to preserve normal speech, swallowing, and appearance functions.
Privo Technologies (搜索) announced the completion of enrollment in Arm 1 of the Phase 2 run-in portion of its ongoing Phase 2/3 clinical trial (CLN-004) evaluating PRV111, a nano-engineered chemotherapy patch designed to treat oral cavity cancers. The Massachusetts-based company reported highly encouraging initial observations regarding both safety and local tumor response, with investigators determining that planned surgical procedures could be cancelled for some patients based on the absence of visible or measurable disease following PRV111 treatment.
Promising Early Results Signal Potential Surgery-Sparing Approach
While detailed results remain under review, the Phase 2 run-in data demonstrated no evidence of systemic toxicity among patients who showed favorable local responses. These findings suggest that PRV111 has the potential to offer a localized, tissue-sparing approach for early-stage oral lesions, though further clinical evaluation and regulatory review are required.
"Completing enrollment in the Phase 2 portion of the CLN-004 study is a pivotal achievement for Privo and our clinical partners," said Dr. Manijeh Goldberg, Chief Executive Officer of Privo Technologies (搜索). "The initial observations are encouraging, and we look forward to sharing the full dataset with the FDA as we prepare for the Phase 3 evaluation."
Novel Nano-Engineered Drug Delivery Platform
PRV111 represents part of Privo's proprietary PRV platform, a family of nano-engineered drug-delivery systems designed to deliver high concentrations of chemotherapy directly to tumor tissue while minimizing systemic exposure. The treatment consists of a topical, transmucosal patch that adheres directly to oral lesions, enabling the delivery of cisplatin nanoparticles through the mucosa to achieve targeted, localized drug penetration.
Each PRV111 application is customized to the size and shape of the patient's tumor, allowing precise coverage of the affected area and consistent drug delivery across complex anatomical surfaces. This non-invasive, localized approach is intended to reduce systemic toxicity compared to conventional chemotherapy and preserve surrounding healthy tissue.
Clinical Trial Design and Patient Population
CLN-004 is an adaptive, open-label Phase 2/3 clinical study evaluating the safety, tolerability, and preliminary efficacy of PRV111 for the localized treatment of oral cavity lesions. In the Phase 2 run-in (Arm 1), enrolled patients were treated with PRV111 as a stand-alone, non-surgical topical therapy for oral carcinoma in situ (CIS) and high-grade oral dysplasia (HGD).
The goal of this stage was to determine whether localized delivery of PRV111 can safely and effectively eliminate pre-cancerous and early-stage cancerous lesions while minimizing the need for surgery. By potentially avoiding extensive surgical excision, PRV111 aims to help patients maintain normal speech, swallowing, and appearance—functions often affected by standard treatment options.
Building on Previous Clinical Success
The CLN-004 study builds upon Privo's earlier clinical experience with PRV111 (CLN-001), which showed promising local tumor responses with no systemic toxicity in a first-in-human setting. The results of that earlier trial were published in Nature Communications and highlighted by Forbes for their innovative approach to localized cancer drug delivery.
Regulatory Path Forward
With Phase 2 enrollment complete, Privo Technologies (搜索) is preparing to submit the CLN-004 dataset to the U.S. FDA. The data from this phase will help inform the design of the pivotal Phase 3 trial, which is planned to further evaluate PRV111 as a localized, non-surgical treatment approach.
"This milestone moves us another step toward providing patients with treatments designed to minimize the life-altering consequences of major surgery," said Dr. Goldberg. "Our platform continues to demonstrate the promise of localized, patient-focused cancer care that aims to improve outcomes while preserving quality of life."